Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 403-412

  Lu, Xiaoxi ^a   Chan, Ting ^a   Xu, Chenghao ^a   Zhu, Ling ^b   Zhou, Qi Tony ^c   Roberts, Kade D ^d   Chan, Hak Kim ^a   Li, Jian ^d   Zhou, Fanfan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PURDUE UNIVERSITY   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; COLISTIN; FLUORESCENT DYE; GLYCYLSARCOSINE; GLYCYLSARCOSINE H 3; MIPS 9541; PEPTIDE TRANSPORTER 2; POLYMYXIN B; POLYMYXIN B1 H 3; POLYMYXIN DERIVATIVE; SOLUTE CARRIER TRANSPORTER; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; COTRANSPORTER; HYDROGEN-COUPLED OLIGOPEPTIDE TRANSPORTER PEPT2; POLYMYXIN;

APICAL MEMBRANE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG UPTAKE; FLUORESCENCE IMAGING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; MOLECULAR BIOLOGY; NEPHROTOXICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSPORT ASSAY; CELL LINE; METABOLISM;

ANTI-BACTERIAL AGENTS; CELL LINE; HUMANS; OPTICAL IMAGING; POLYMYXINS; SYMPORTERS;

EID: 84959906638     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv340     Document Type: Article

References (75)

1. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: 630-6.
2. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005; 36: 697-705.
3. Ritchie DJ, Alexander BT, Finnegan PM. New antimicrobial agents for use in the intensive care unit. Infect Dis Clin North Am 2009; 23: 665-81.
4. CDC. Antibiotic Resistance Threats in US. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/.
5. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
6. Velkov T, Roberts KD, Nation RL et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 2013; 8: 711-24.
7. Nation RL, Li J, Cars O et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15: 225-34.
8. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
9. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
10. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
11. Ainsworth GC, Brown AM, Brownlee G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature 1947; 159: 263.
12. Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. J Bacteriol 1947; 54: 24.
13. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
14. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
15. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol 1967; 93: 1463-4.
16. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31.
17. Azad MA, Roberts KD, Yu HH et al. Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach. Anal Chem 2015; 87: 1590-5.
18. Li J, Milne RW, Nation RL et al. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47: 1766-70.
19. Ma Z, Wang J, Nation RL et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 2009; 53: 2857-64.
20. Zavascki AP, Goldani LZ, Cao G et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47: 1298-304.
21. Suzuki T, Yamaguchi H, Ogura J et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 2013; 57: 6319-24.
22. Abdelraouf K, Chang KT, Yin T et al. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 2014; 58: 4200-2.
23. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012; 165: 1260-87.
24. Zhou F, You G. Molecular insights into the structure-function relationship of organic anion transporters OATs. Pharm Res 2007; 24: 28-36.
25. Smith DE, Clemencon B, Hediger MA. Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med 2013; 34: 323-36.
26. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005; 20: 452-77.
27. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2008; 23: 22-44.
28. Bretschneider B, Brandsch M, Neubert R. Intestinal transport of β-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 1999; 16: 55-61.
29. Luckner P, Brandsch M. Interaction of 31 β-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm 2005; 59: 17-24.
30. Wenzel U, Gebert I, Weintraut H et al. Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther 1996; 277: 831-9.
31. Ganapathy ME, Brandsch M, Prasad PD et al. Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 1995; 270: 25672-7.
32. Deris ZZ, Swarbrick JD, Roberts KD et al. Probing the penetration of antimicrobial polymyxin lipopeptides into Gram-negative bacteria. Bioconjug Chem 2014; 25: 750-60.
33. Li Z, Wang K, Zheng J et al. Interactions of the active components of Punica granatum (pomegranate) with the essential renal and hepatic human solute carrier transporters. Pharm Biol 2014; 52: 1510-7.
34. Li Z, Cheung FS, Zheng J et al. Interaction of the bioactive flavonol, icariin, with the essential human solute carrier transporters. J Biochem Mol Toxicol 2014; 28: 91-7.
35. Johnston RA, Rawling T, Chan T et al. Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metab Dispos 2014; 42: 1851-7.
36. Xu F, Li Z, Zheng J et al. The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential solute carrier transporters. J Pharm Sci 2013; 102: 4205-11.
37. Zhou F, Zhu L, Cui PH et al. Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol 2010; 159: 419-27.
38. Zheng J, Chan T, Cheung FS et al. PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability. PLoS One 2014; 9: e94712.
39. Zhou F, Hong M, You G. Regulation of human organic anion transporter 4. by progesterone and protein kinase C in human placental BeWo cells. Am J Physiol Endocrinol Metab 2007; 293: E57-61.
40. Zhou F, Illsley NP, You G. Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells. Eur J Pharm Sci 2006; 27: 518-23.
41. Zhou F, Lee AC, Krafczyk K et al. Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 2011; 162: 1380-8.
42. Zhou F, Xu W, Tanaka K et al. Comparison of the interaction of human organic anion transporter hOAT4 with PDZ proteins between kidney cells and placental cells. Pharm Res 2008; 25: 475-80.
43. Zhou F, Zheng J, Zhu L et al. Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2. AAPS J 2013; 15: 1099-108.
44. Chan T, Zheng J, Zhu L et al. Putative transmembrane domain 6 of the human organic anion transporting polypeptide 1A2 (OATP1A2) influences transporter substrate binding, protein trafficking, and quality control. Mol Pharm 2015; 12: 111-9.
45. Kobayashi Y, Ohshiro N, Sakai R et al. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005; 57: 573-8.
46. Hong M, Zhou F, You G. Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1. J Biol Chem 2004; 279: 31478-82.
47. Hirano M, Maeda K, Shitara Y et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-46.
48. Amphoux A, Millan MJ, Cordi A et al. Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: a comparison to human α1-and α2-adrenoceptor subtypes. Eur J Pharmacol 2010; 634: 1-9.
49. Toh DS, Cheung FS, MurrayM et al. Functional analysis of novel variants in the organic cation/ergothioneine transporter 1 identified in Singapore populations. Mol Pharm 2013; 10: 2509-16.
50. Toh DS, Murray M, Pern Tan K et al. Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochem Pharmacol 2011; 82: 1692-9.
51. Guo X, Meng Q, Liu Q et al. Construction, identification and application of HeLa cells stably transfected with human PEPT1 and PEPT2. Peptides 2012; 34: 395-403.
52. Noshiro R, Anzai N, Sakata T et al. The PDZ domain protein PDZK1 interacts with human peptide transporter PEPT2 and enhances its transport activity. Kidney Int 2006; 70: 275-82.
53. Ocheltree SM, Shen H, Hu Y et al. Role and relevance of peptide transporter 2(PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 2005; 315: 240-7.
54. Azad MA, Akter J, Rogers KL et al. Major pathways of polymyxininduced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother 2015; 59: 2136-43.
55. Azad MA, Yun B, Roberts KD et al. Measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe? Antimicrob Agents Chemother 2014; 58: 6337-8.
56. Spapen H, Jacobs R, Van Gorp V et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1: 14.
57. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
58. Ocheltree SM, Shen H, Hu Y et al. Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: studies in wild-type and null mice. Pharm Res 2004; 21: 1680-5.
59. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
60. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
61. Abdelraouf K, He J, Ledesma KR et al. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012; 56: 5724-7.
62. He H, Li JC, Nation RL et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 2013; 68: 2311-7.
63. He J, Abdelraouf K, Ledesma KR et al. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents 2013; 42: 559-64.
64. Koomanachai P, Landersdorfer CB, Chen G et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2014; 58: 440-6.
65. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-92.
66. Li J, Milne RW, Nation RL et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53: 837-40.
67. Dai C, Li J, Tang S et al. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 2014; 58: 4075-85.
68. You G, Morris M. Drug transporters-molecular characterisation and role in drug disposition. 2007: 619-63.
69. Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 2004; 447: 610-8.
70. Biegel A, Knutter I, Hartrodt B et al. The renal type H+/peptide symporter PEPT2: structure-affinity relationships. Amino Acids 2006; 31: 137-56.
71. Biegel A, Gebauer S, Brandsch M et al. Structural requirements for the substrates of the H+/peptide cotransporter PEPT2 determined by three-dimensional quantitative structure-activity relationship analysis. J Med Chem 2006; 49: 4286-96.
72. Shen H, Smith DE, Yang T et al. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol 1999; 276: F658-65.
73. Smith DE, Pavlova A, Berger UV et al. Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm Res 1998; 15: 1244-9.
74. Doring F, Will J, Amasheh S et al. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J Biol Chem 1998; 273: 23211-8.
75. Ali FE, Cao G, Poudyal A et al. Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. J Antimicrob Chemother 2009; 64: 1067-70.